Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Clin Chem Lab Med. 2019 Jun 26;57(7):1053-1062. doi: 10.1515/cclm-2018-1048.
Background Extracellular vesicle (EV)-associated microRNAs (miRNAs) have been suggested as promising biomarkers for blood-based cancer diagnosis. However, one of the major limitations for the use of EVs with diagnostic purpose is the lack of standardized EV-profiling techniques. In this regard, the objective of our study was to design an integrated next-generation sequencing (NGS)-based workflow for analyzing the signature of EV-associated miRNA in the plasma of platinum-resistant ovarian cancer patients. Methods For EV-extraction, different enrichment methods were compared (ExoQuick vs. exoRNeasy). NGS was performed with the Illumina platform. Results We established an integrated NGS-based workflow, including EV-enrichment with the ExoQuick system, which resulted in an optimal RNA-yield and consistent small RNA libraries. We applied this workflow in a pilot cohort of clinically documented platinum-sensitive (n=15) vs. platinum-resistant (n=15) ovarian cancer patients, resulting in a panel of mature EV-associated miRNAs (including ovarian cancer associated miR-181a, miR-1908, miR-21, miR-486 and miR-223), which were differentially abundant in the plasma of platinum-resistant patients. Conclusions This is the first study, analyzing the profile of EV-associated miRNAs in platinum-resistant ovarian cancer patients. We provide rationale to further validate these miRNA candidates in an independent set of patients, in order to characterize their biomarker potential as predictors for platinum-resistance.
细胞外囊泡(EV)相关 microRNAs(miRNAs)已被认为是基于血液的癌症诊断有前途的生物标志物。然而,将 EV 用于诊断目的的主要限制之一是缺乏标准化的 EV 分析技术。在这方面,我们研究的目的是设计一种集成的下一代测序(NGS)分析方法,用于分析铂耐药卵巢癌患者血浆中 EV 相关 miRNA 的特征。
对于 EV 提取,比较了不同的富集方法(ExoQuick 与 exoRNeasy)。使用 Illumina 平台进行 NGS。
我们建立了一种集成的 NGS 工作流程,包括使用 ExoQuick 系统进行 EV 富集,这导致了最佳的 RNA 产量和一致的小 RNA 文库。我们将此工作流程应用于一组临床记录的铂敏感(n=15)与铂耐药(n=15)卵巢癌患者的试点队列中,结果得到了一组成熟的 EV 相关 miRNA(包括卵巢癌相关 miR-181a、miR-1908、miR-21、miR-486 和 miR-223),这些 miRNA 在铂耐药患者的血浆中丰度不同。
这是第一项分析铂耐药卵巢癌患者 EV 相关 miRNA 谱的研究。我们为进一步在独立患者组中验证这些 miRNA 候选物提供了依据,以表征它们作为铂耐药预测因子的生物标志物潜力。